{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:55:38Z","timestamp":1793498138307,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.eprac.2025.09.204","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:05:11Z","timestamp":1759341911000},"page":"201-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Belzutifan for HIF2A-Related Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0861-9348","authenticated-orcid":false,"given":"Hussam","family":"Alkaissi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Talvacchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberta","family":"Derkyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Gubbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Pappo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Glod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengping","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.eprac.2025.09.204_bib1","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.eprac.2022.09.003","article-title":"New biology of pheochromocytoma and Paraganglioma","volume":"28","author":"Pacak","year":"2022","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2025.09.204_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgac563","article-title":"Recurrent disease in patients with sporadic pheochromocytoma and Paraganglioma","volume":"108","author":"Li","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.204_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75354-9","article-title":"Long-term outcomes and prognostic factors of metastatic or recurrent pheochromocytoma and paraganglioma: a 20-year review in a single institution","volume":"14","author":"Ishizaki","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.eprac.2025.09.204_bib4","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1210\/clinem\/dgaf259","article-title":"Approach to the patient with metastatic pheochromocytoma and Paraganglioma","volume":"110","author":"Alkaissi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2025.09.204_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.eprac.2025.09.204_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and Paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.204_bib7","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/ERC-13-0101","article-title":"In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas","volume":"20","author":"Toledo","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.eprac.2025.09.204_bib8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and Paraganglioma","volume":"43","author":"Nolting","year":"2022","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.eprac.2025.09.204_bib9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/cancers14030594","article-title":"New insights on the genetics of pheochromocytoma and Paraganglioma and its clinical implications","volume":"14","author":"Jhawar","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.eprac.2025.09.204_bib10","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible Factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eprac.2025.09.204_bib11","series-title":"FDA Approves Belzutifan for Advanced Renal Cell Carcinoma","year":"2023"},{"key":"10.1016\/j.eprac.2025.09.204_bib13","series-title":"FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease","year":"2022"},{"issue":"16","key":"10.1016\/j.eprac.2025.09.204_bib14","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMc2409427","article-title":"Rapid cardiovascular response to Belzutifan in HIF2A-Mediated paraganglioma","volume":"391","author":"Alkaissi","year":"2024","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2025.09.204_bib15","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","article-title":"Belzutifan, a potent HIF2alpha inhibitor, in the pacak-zhuang syndrome","volume":"385","author":"Kamihara","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.eprac.2025.09.204_bib16","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.09.204_bib17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-Inducible factor 2 alpha (HIF2alpha) inhibitors: targeting genetically driven tumor hypoxia","volume":"44","author":"Toledo","year":"2023","journal-title":"Endocr Rev"},{"issue":"10","key":"10.1016\/j.eprac.2025.09.204_bib18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(24)00389-9","article-title":"Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study","volume":"25","author":"Iliopoulos","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.eprac.2025.09.204_bib19","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.eprac.2025.09.204_bib20","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMc2411843","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Alkaissi","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2025.09.204_bib21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.09.204_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101955","article-title":"Current views on the role of HIF-2alpha in the pathogenesis and syndromic presentation of pheochromocytoma and paraganglioma","volume":"38","author":"Bechmann","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.204_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-38606-8","article-title":"Cytoplasmic HIF-2alpha as tissue biomarker to identify metastatic sympathetic paraganglioma","volume":"13","author":"Karakaya","year":"2023","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.eprac.2025.09.204_bib24","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.drudis.2019.09.008","article-title":"Allosteric inhibition of HIF-2alpha as a novel therapy for clear cell renal cell carcinoma","volume":"24","author":"Yu","year":"2019","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.204_bib25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12871-020-01212-6","article-title":"Preoperative intravenous rehydration for patients with pheochromocytomas and paragangliomas: is it necessary? A propensity score matching analysis","volume":"20","author":"Kong","year":"2020","journal-title":"BMC Anesthesiol"},{"issue":"24","key":"10.1016\/j.eprac.2025.09.204_bib26","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating Tumor DNA analysis guiding adjuvant therapy in stage II Colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.09.204_bib27","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1038\/s41467-024-51718-7","article-title":"Adipocyte deletion of the oxygen-sensor PHD2 sustains elevated energy expenditure at thermoneutrality","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"issue":"7675","key":"10.1016\/j.eprac.2025.09.204_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nature24277","article-title":"Genetic effects on gene expression across human tissues","volume":"550","author":"GTEx Consortium","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.eprac.2025.09.204_bib29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1165\/rcmb.2011-0024OC","article-title":"Hypoxia-inducible factor 2alpha plays a critical role in the formation of alveoli and surfactant","volume":"46","author":"Huang","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"8064","key":"10.1016\/j.eprac.2025.09.204_bib30","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41586-025-08898-z","article-title":"BMAL1-HIF2A heterodimer modulates circadian variations of myocardial injury","volume":"641","author":"Ruan","year":"2025","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.eprac.2025.09.204_bib31","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1161\/CIRCRESAHA.123.324054","article-title":"EPAS1 Attenuates atherosclerosis initiation at disturbed flow sites through endothelial fatty acid uptake","volume":"135","author":"Pirri","year":"2024","journal-title":"Circ Res"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25012297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25012297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:58:26Z","timestamp":1778817506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25012297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1530891X25012297"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.09.204","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Belzutifan for HIF2A-Related Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.09.204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}